Comparison · NCT01335867-290eafa0
Vigabatrin vs Placebo: Disease Severity and Improvement
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vigabatrin vs Placebo: Disease Severity and Improvement. Trial comparisons, record NCT01335867-290eafa0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01335867-290eafa0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.313 | 0.142 | 0.556 | wilson | |
| Risk in group 2 | 0.125 | 0.035 | 0.36 | wilson | |
| Risk difference, group 1 minus group 2 | 0.188 | -0.103 | 0.447 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.5 | 0.566 | 11.1 | log | |
| Odds ratio, group 1 over group 2 | 3.18 | 0.516 | 19.6 | log | |
| Number needed to treat, for one more participant with the outcome on Vigabatrin than on Placebo | 5.33 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vigabatrin | Vigabatrin titrated to 3 grams daily for 12 weeks~Vigabatrin: Vigabatrin escalated to 3 grams daily for 8 weeks | 5 | 16 | OG000 |
| Group 2 | Placebo | Identical placebo daily for 12 weeks~Placebo: Placebo pills | 2 | 16 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Disease Severity and Improvement
- Description
- Number of subjects in each group rated as improved or very much improved at the end of the trial
- Time frame
- 8 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- Vigabatrin for Cocaine and Alcohol Dependence
- NCT number
- NCT01335867
- Phases
- PHASE2
- Conditions
- Alcoholism, Cocaine Dependence
- Interventions
- Vigabatrin, Placebo
- Lead sponsor
- University of Pennsylvania
- Results first posted
- 2015-06-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01335867?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01335867-290eafa0